OXIS CEO Steve Guillen to Highlight Company's Technology Development Strategy at Rodman & Renshaw Techvest Global Healthcare Conference

Business Wire, April 26, 2005

PORTLAND, Ore. -- Steve Guillen, who was appointed President and Chief Executive Officer of OXIS International, Inc. (OTCBB:OXIS) (Nouveau Marche:OXIS) in February of 2005, will make his first public address outlining the company's future direction at the upcoming Techvest Global Healthcare Conference on May 4th in Paris.

"Since I joined OXIS, we have been actively prioritizing the portfolio of technologies that OXIS has pioneered and now we plan to unveil the OXIS roadmap moving forward," stated Guillen. "It has been challenging due to the wealth of technologies assembled by the company during its extensive history developing oxidative stress products. We are now ready to reveal our immediate areas of focus as well as some exciting longer-term opportunities."

The presentation by Mr. Guillen will be broadcast worldwide over the Internet in a live Web cast. The presentation is scheduled for 3:10 Paris time (9:10 am Eastern Daylight Time) on May 4, 2005. Viewers can access the free Web cast at: http://www.wsw.com/webcast/rrshq5/oxis.ob/; an archive of the presentation will be available for viewing for 90 days after the presentation.

OXIS has established a leadership position in commercialized oxidative-stress assays, including its myeloperoxidase assay used to predict early risks of cardiovascular diseases. The company is the leading producer of the powerful antioxidant Ergothioneine, currently used as an anti-aging agent in skin-care products and soon to be introduced into the neutraceutical marketplace. The company also holds the rights to three therapeutic classes of compounds in the area of oxidative stress.

About OXIS International

OXIS International Inc., headquartered in Portland, Oregon, focuses on developing technologies and products to research, diagnose, treat and prevent diseases associated with damage from free radical and reactive oxygen species. For more information, go to: www.OXIS.com.

Statements in this release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, any statements regarding beliefs, plans, estimates, projections, expectations, goals or intentions regarding the future, such as statements relating to: the wealth of technologies assembled by the company; exciting longer-term opportunities; the company's leadership position in commercialized oxidative-stress assays; and the company being the leading producer of the powerful antioxidant Ergothioneine, currently used as an anti-aging agent in skin-care products which will soon be introduced into the neutraceutical marketplace . The forward-looking statements in this release involve important factors that could cause actual results to differ materially from those in the forward-looking statements. Such important factors include risks and uncertainties, including, but not limited to, unanticipated changes in present and future objectives of the Company; unanticipated difficulties in implementing the Company's current and future business strategies; unforeseen difficulties related to the Company's oxidative stress and other diagnostic products; and other risks indicated in the Company's filings with the Securities and Exchange Commission. It is important to note that actual outcomes could differ materially from those in such forward-looking statements. Readers should also refer to the documents filed by the Company with the Securities and Exchange Commission, specifically the annual report on Form 10-KSB for the year ended December 31, 2004, filed with the Securities and Exchange Commission on February 25, 2005.